Skip to main content
Top
Published in: Clinical Rheumatology 6/2009

01-06-2009 | Original Article

A comparative study of arterial stiffness, flow-mediated vasodilation of the brachial artery, and the thickness of the carotid artery intima–media in patients with systemic autoimmune diseases

Authors: Pál Soltész, Henriett Dér, György Kerekes, Péter Szodoray, Gabriella Szücs, Katalin Dankó, Yehuda Shoenfeld, Gyula Szegedi, Zoltán Szekanecz

Published in: Clinical Rheumatology | Issue 6/2009

Login to get access

Abstract

Patients with autoimmune diseases may have increased vascular risk leading to higher mortality rates. Novel imaging techniques are necessary for the early assessment and management of these patients. In this study, we compared augmentation index (AIx) and pulse wave velocity (PWV), indicators of arterial stiffness, to brachial arterial flow-mediated vasodilation (FMD) and common carotid artery intima–media thickness (ccIMT), standard indicators of endothelial dysfunction and atherosclerosis, respectively. We wished to assess the vascular status of autoimmune patients by using a novel, cheap, and reproducible technique, the arteriograph. Altogether, 101 patients with systemic autoimmune diseases including primary antiphospholipid syndrome, systemic sclerosis, rheumatoid arthritis, and polymyositis, all having various types of vasculopathies, as well as 36 healthy individuals were investigated. Arterial stiffness was assessed by a TensioClinic arteriograph, a recently validated technique. Brachial arterial FMD and ccIMT were determined using high-resolution ultrasonography. Autoimmune patients exerted impaired FMD (3.7 ± 3.8%), increased ccIMT (0.7 ± 0.2 mm), AIx (1.2 ± 32.2%), and PWV (9.7 ± 2.4 m/s) in comparison to control subjects (FMD = 8.4 ± 4.0%; ccIMT = 0.6 ± 0.1 mm; Aix = −41.1 ± 22.5%; PWV = 8.0 ± 1.5 m/s; p < 0.05). We found a significant negative correlation of FMD with AIx (R = −0.64; p < 0.0001) and PWV (R = −0.37; p = 0.00014). There were significant positive correlations between ccIMT and AIx (R = 0.34; p = 0.0009), ccIMT and PWV (R = 0.44; p < 0.0001), as well as AIx and PWV (R = 0.47; p < 0.0001). AIx, PWV, and ccIMT positively correlated and FMD negatively correlated with the age of the autoimmune patients. Arterial stiffness indicated by increased AIx and PWV may be strongly associated with endothelial dysfunction and overt atherosclerosis in patients with autoimmune diseases. Assessment of arterial stiffness, FMD, and ccIMT are reproducible and reliable noninvasive techniques for the complex assessment of vascular abnormalities in patients at high risk.
Literature
1.
go back to reference Hadi HA, Carr CS, Al Suwaidi J (2005) Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome. Vasc Health Risk Manag 1:183–198PubMed Hadi HA, Carr CS, Al Suwaidi J (2005) Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome. Vasc Health Risk Manag 1:183–198PubMed
2.
go back to reference Blacher J, Pannier B, Guerin AP, Marchais SJ, Safar ME, London GM (1998) Carotid arterial stiffness as a predictor of cardiovascular and all-cause mortality in end-stage renal disease. Hypertension 32:570–574PubMed Blacher J, Pannier B, Guerin AP, Marchais SJ, Safar ME, London GM (1998) Carotid arterial stiffness as a predictor of cardiovascular and all-cause mortality in end-stage renal disease. Hypertension 32:570–574PubMed
3.
go back to reference Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM (1999) Impact of aortic stiffness on survival in end-stage renal disease. Circulation 99:2434–2439PubMed Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM (1999) Impact of aortic stiffness on survival in end-stage renal disease. Circulation 99:2434–2439PubMed
4.
go back to reference Rosenfeld ME (2000) An overview of the evaluation of the atherosclerotic plaque: from fatty streak to plaque rupture and thrombosis. Z Kardiol 89:VII/2–VII/6CrossRef Rosenfeld ME (2000) An overview of the evaluation of the atherosclerotic plaque: from fatty streak to plaque rupture and thrombosis. Z Kardiol 89:VII/2–VII/6CrossRef
5.
go back to reference Veres K, Lakos G, Kerényi A, Szekanecz Z, Szegedi G, Shoenfeld Y, Soltész P (2004) Antiphospholipid antibodies in acute coronary syndrome: implications for pathogenesis and prognosis. Lupus 13:423–427PubMedCrossRef Veres K, Lakos G, Kerényi A, Szekanecz Z, Szegedi G, Shoenfeld Y, Soltész P (2004) Antiphospholipid antibodies in acute coronary syndrome: implications for pathogenesis and prognosis. Lupus 13:423–427PubMedCrossRef
6.
go back to reference Szodoray P, Timár O, Veres K, Der H, Szomjak E, Lakos G, Aleksza M, Nakken B, Szegedi G, Soltesz P (2006) Th1/Th2 imbalance, measured by circulating and intracytoplasmic inflammatory cytokines—immunological alterations in acute coronary syndrome and stable coronary artery disease. Scand J Immunol 64:336–344PubMedCrossRef Szodoray P, Timár O, Veres K, Der H, Szomjak E, Lakos G, Aleksza M, Nakken B, Szegedi G, Soltesz P (2006) Th1/Th2 imbalance, measured by circulating and intracytoplasmic inflammatory cytokines—immunological alterations in acute coronary syndrome and stable coronary artery disease. Scand J Immunol 64:336–344PubMedCrossRef
7.
go back to reference Shoenfeld Y, Gerli R, Doria A, Matsuura E, Matucci-Cerinic M, Ronda N, Jara LJ, Abu-Shakra M, Meroni PL, Sherer Y (2005) Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 112:3337–3347PubMedCrossRef Shoenfeld Y, Gerli R, Doria A, Matsuura E, Matucci-Cerinic M, Ronda N, Jara LJ, Abu-Shakra M, Meroni PL, Sherer Y (2005) Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 112:3337–3347PubMedCrossRef
8.
go back to reference Sherer Y, Shoenfeld Y (2006) Mechanisms of disease: atherosclerosis in autoimmune diseases. Nat Clin Pract Rheumatol 2:99–106PubMedCrossRef Sherer Y, Shoenfeld Y (2006) Mechanisms of disease: atherosclerosis in autoimmune diseases. Nat Clin Pract Rheumatol 2:99–106PubMedCrossRef
9.
go back to reference Szekanecz Z, Kerekes G, Dér H, Sándor Z, Szabó Z, Végvári A, Simkovics E, Soós L, Szentpétery A, Besenyei T, Szücs G, Szántó S, Tamási L, Szegedi G, Shoenfeld Y, Soltész P (2007) Accelerated atherosclerosis in rheumatoid arthritis. Ann N Y Acad Sci 1108:349–358PubMedCrossRef Szekanecz Z, Kerekes G, Dér H, Sándor Z, Szabó Z, Végvári A, Simkovics E, Soós L, Szentpétery A, Besenyei T, Szücs G, Szántó S, Tamási L, Szegedi G, Shoenfeld Y, Soltész P (2007) Accelerated atherosclerosis in rheumatoid arthritis. Ann N Y Acad Sci 1108:349–358PubMedCrossRef
10.
go back to reference Kerekes G, Szekanecz Z, Dér H, Sándor Z, Lakos G, Muszbek L, Csipő I, Sipka S, Seres I, Paragh G, Kappelmayer J, Szomják E, Veres K, Szegedi G, Shoenfeld Y, Soltész P (2008) Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: a multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity. J Rheumatol 35:398–406PubMed Kerekes G, Szekanecz Z, Dér H, Sándor Z, Lakos G, Muszbek L, Csipő I, Sipka S, Seres I, Paragh G, Kappelmayer J, Szomják E, Veres K, Szegedi G, Shoenfeld Y, Soltész P (2008) Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: a multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity. J Rheumatol 35:398–406PubMed
11.
go back to reference Giles JT, Post W, Blumenthal RS, Bathon JM (2006) Therapy insight: managing cardiovascular risk in patients with rheumatoid arthritis. Nat Clin Pract Rheumatol 2:320–329PubMedCrossRef Giles JT, Post W, Blumenthal RS, Bathon JM (2006) Therapy insight: managing cardiovascular risk in patients with rheumatoid arthritis. Nat Clin Pract Rheumatol 2:320–329PubMedCrossRef
12.
go back to reference Soltész P, Szekanecz Z, Kiss E, Shoenfeld Y (2007) Cardiac manifestations in antiphospholipid syndrome. Autoimmun Rev 6:379–386PubMedCrossRef Soltész P, Szekanecz Z, Kiss E, Shoenfeld Y (2007) Cardiac manifestations in antiphospholipid syndrome. Autoimmun Rev 6:379–386PubMedCrossRef
13.
go back to reference Dér H, Kerekes G, Veres K, Szodoray P, Toth J, Lakos G, Szegedi G, Soltész P (2007) Impaired endothelial function and increased carotid intima–media thickness in association with elevated von Willebrand antigen level in primary antiphospholipid syndrome. Lupus 16:497–503PubMedCrossRef Dér H, Kerekes G, Veres K, Szodoray P, Toth J, Lakos G, Szegedi G, Soltész P (2007) Impaired endothelial function and increased carotid intima–media thickness in association with elevated von Willebrand antigen level in primary antiphospholipid syndrome. Lupus 16:497–503PubMedCrossRef
14.
go back to reference Shoenfeld Y, Harats D, George J (1998) Atherosclerosis and the antiphospholipid syndrome: a link unravelled. Lupus 7(suppl):140–143CrossRef Shoenfeld Y, Harats D, George J (1998) Atherosclerosis and the antiphospholipid syndrome: a link unravelled. Lupus 7(suppl):140–143CrossRef
15.
go back to reference Jara LJ, Medina G, Vera-Lastra O, Shoenfeld Y (2003) Atherosclerosis and antiphospholipid syndrome. Clin Rev Allergy Immunol 25:79–87PubMedCrossRef Jara LJ, Medina G, Vera-Lastra O, Shoenfeld Y (2003) Atherosclerosis and antiphospholipid syndrome. Clin Rev Allergy Immunol 25:79–87PubMedCrossRef
16.
go back to reference Shoenfeld Y, Wu R, Dearing LD, Matsuura E (2004) Are anti-oxidized low-density lipoprotein antibodies pathogenic or protective. Circulation 110:2552–2558PubMedCrossRef Shoenfeld Y, Wu R, Dearing LD, Matsuura E (2004) Are anti-oxidized low-density lipoprotein antibodies pathogenic or protective. Circulation 110:2552–2558PubMedCrossRef
17.
go back to reference Shoenfeld Y, Haratz D, Jacob G (2000) Heat shock protein 60/50, beta2-glycoprotein I and Oxidized LDL as players in murine atherosclerosis. J Autoimmunity 15:199–202CrossRef Shoenfeld Y, Haratz D, Jacob G (2000) Heat shock protein 60/50, beta2-glycoprotein I and Oxidized LDL as players in murine atherosclerosis. J Autoimmunity 15:199–202CrossRef
18.
go back to reference Sherer Y, Gerli R, Gilburd B, Bartoloni Bocci E, Vaudo G, Mannarino E, Shoenfeld Y (2007) Thickened carotid artery intima–media in rheumatoid arthritis is associated with elevated anticardiolipin antibodies. Lupus 16:259–264PubMedCrossRef Sherer Y, Gerli R, Gilburd B, Bartoloni Bocci E, Vaudo G, Mannarino E, Shoenfeld Y (2007) Thickened carotid artery intima–media in rheumatoid arthritis is associated with elevated anticardiolipin antibodies. Lupus 16:259–264PubMedCrossRef
19.
go back to reference van Doornum S, McColl G, Wicks IP (2002) Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis. Arthritis Rheum 46:862–873PubMedCrossRef van Doornum S, McColl G, Wicks IP (2002) Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis. Arthritis Rheum 46:862–873PubMedCrossRef
20.
go back to reference Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, Stampfer MJ, Curhan GC (2003) Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 107:1303–1307PubMedCrossRef Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, Stampfer MJ, Curhan GC (2003) Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 107:1303–1307PubMedCrossRef
21.
go back to reference Szücs G, Tímár O, Szekanecz Z, Dér H, Kerekes G, Szamosi S, Shoenfeld Y, Szegedi G, Soltész P (2007) Endothelial dysfunction precedes atherosclerosis in systemic sclerosis—relevance for prevention of vascular complications. Rheumatology 46:759–762PubMedCrossRef Szücs G, Tímár O, Szekanecz Z, Dér H, Kerekes G, Szamosi S, Shoenfeld Y, Szegedi G, Soltész P (2007) Endothelial dysfunction precedes atherosclerosis in systemic sclerosis—relevance for prevention of vascular complications. Rheumatology 46:759–762PubMedCrossRef
22.
go back to reference Matucci-Cerinic M, Fiori G, Grenbaum E, Shoenfeld Y (2003) Macrovascular disease in systemic sclerosis. In: Furst D, Clements P (eds) Systemic sclerosis. Lippincott Williams and Wilkins, Baltimore, MD, p 241 Matucci-Cerinic M, Fiori G, Grenbaum E, Shoenfeld Y (2003) Macrovascular disease in systemic sclerosis. In: Furst D, Clements P (eds) Systemic sclerosis. Lippincott Williams and Wilkins, Baltimore, MD, p 241
23.
go back to reference Pignone A, Scaletti C, Matucci-Cerinic M, Vazquez-Abad D, Meroni PL, Del Papa N, Falcini F, Generini S, Rothfield N, Cagnoni M (1998) Anti-endothelial cell antibodies in systemic sclerosis: significant association with vascular involvement and alveolo-capillary impairment. Clin Exp Rheumatol 16:527–532PubMed Pignone A, Scaletti C, Matucci-Cerinic M, Vazquez-Abad D, Meroni PL, Del Papa N, Falcini F, Generini S, Rothfield N, Cagnoni M (1998) Anti-endothelial cell antibodies in systemic sclerosis: significant association with vascular involvement and alveolo-capillary impairment. Clin Exp Rheumatol 16:527–532PubMed
24.
go back to reference Fatini C, Guiducci S, Abbate R, Matucci-Cerinic M (2004) Vascular injury in systemic sclerosis: angiotensin-converting enzyme insertion/deletion polymorphism. Curr Rheumatol Rep 6:149–155PubMedCrossRef Fatini C, Guiducci S, Abbate R, Matucci-Cerinic M (2004) Vascular injury in systemic sclerosis: angiotensin-converting enzyme insertion/deletion polymorphism. Curr Rheumatol Rep 6:149–155PubMedCrossRef
25.
go back to reference Andersen GN, Caidahl K, Kazzam E, Petersson AS, Waldenstrom A, Mincheva-Nilsson L, Rantapaa-Dahlqvist S (2000) Correlation between increased nitric oxide production and markers of endothelial activation in systemic sclerosis: findings with the soluble adhesion molecule E selectin, intercellular adhesion molecule 1 and vascular adhesion molecule 1. Arthritis Rheum 43:1085–1093PubMedCrossRef Andersen GN, Caidahl K, Kazzam E, Petersson AS, Waldenstrom A, Mincheva-Nilsson L, Rantapaa-Dahlqvist S (2000) Correlation between increased nitric oxide production and markers of endothelial activation in systemic sclerosis: findings with the soluble adhesion molecule E selectin, intercellular adhesion molecule 1 and vascular adhesion molecule 1. Arthritis Rheum 43:1085–1093PubMedCrossRef
26.
27.
go back to reference Stern R, Godbold JH, Chess Q, Kagen LJ (1984) ECG abnormalities in polymyositis. Arch Intern Med 144:2185–2189PubMedCrossRef Stern R, Godbold JH, Chess Q, Kagen LJ (1984) ECG abnormalities in polymyositis. Arch Intern Med 144:2185–2189PubMedCrossRef
28.
go back to reference Dankó K, Ponyi A, Constantin T, Borgulya G, Szegedi G (2004) Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases. Medicine (Baltimore) 83:35–42CrossRef Dankó K, Ponyi A, Constantin T, Borgulya G, Szegedi G (2004) Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases. Medicine (Baltimore) 83:35–42CrossRef
29.
go back to reference Baulmann J, Schillings U, Rickert S, Uen S, Düsing R, Cziraki A, Illyes M, Mengden T (2008) A new oscillometric method for assessment of arterial stiffness: comparison with tonometric and piezo-electronic methods. J Hypertens 26:523–528PubMedCrossRef Baulmann J, Schillings U, Rickert S, Uen S, Düsing R, Cziraki A, Illyes M, Mengden T (2008) A new oscillometric method for assessment of arterial stiffness: comparison with tonometric and piezo-electronic methods. J Hypertens 26:523–528PubMedCrossRef
30.
go back to reference Baulmann J, Homsi R, Uen S, Vetter H, Dusing R, Mengden T (2004) Arterial stiffness in arterial hypertension. A new risk factor for left ventricular hypertrophy and cardiac insufficiency. Dtsch Med Wochenschr 129:447–452PubMedCrossRef Baulmann J, Homsi R, Uen S, Vetter H, Dusing R, Mengden T (2004) Arterial stiffness in arterial hypertension. A new risk factor for left ventricular hypertrophy and cardiac insufficiency. Dtsch Med Wochenschr 129:447–452PubMedCrossRef
31.
go back to reference Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, Lloyd JK, Deanfield JE (1992) Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 340:1111–1115PubMedCrossRef Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, Lloyd JK, Deanfield JE (1992) Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 340:1111–1115PubMedCrossRef
32.
go back to reference Doshi SN, Lewis MJ, Goodfellow J (2001) Improving endothelial vasomotor function. BMJ 323:352–353PubMedCrossRef Doshi SN, Lewis MJ, Goodfellow J (2001) Improving endothelial vasomotor function. BMJ 323:352–353PubMedCrossRef
33.
go back to reference Magometschnigg D (2005) Blood pressure and arterial stiffness. A comparison of two devices for measuring augmentation index and pulse wave velocity. Wien Med Wochenschr 155:404–410PubMedCrossRef Magometschnigg D (2005) Blood pressure and arterial stiffness. A comparison of two devices for measuring augmentation index and pulse wave velocity. Wien Med Wochenschr 155:404–410PubMedCrossRef
34.
go back to reference Corretti MC, Anderson TJ, Benjamin EJ, Celemajer DS, Charbonneau F, Creager MA, Deanfield JE, Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J, Vogel R, International Brachial Artery Reactivity Task Force (2002) Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 39:257–265PubMedCrossRef Corretti MC, Anderson TJ, Benjamin EJ, Celemajer DS, Charbonneau F, Creager MA, Deanfield JE, Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J, Vogel R, International Brachial Artery Reactivity Task Force (2002) Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 39:257–265PubMedCrossRef
35.
go back to reference Kelm M (2002) Flow-mediated dilatation in human circulation: diagnostic and therapeutic aspects. Am J Physiol Heart Circ Physiol 282:1–5 Kelm M (2002) Flow-mediated dilatation in human circulation: diagnostic and therapeutic aspects. Am J Physiol Heart Circ Physiol 282:1–5
36.
go back to reference Kanters SDJM, Algra A, van Leeuwen MS, Banga JD (1997) Reproducibility of in vivo carotid intima–media thickness measurements. Stroke 28:665–671PubMed Kanters SDJM, Algra A, van Leeuwen MS, Banga JD (1997) Reproducibility of in vivo carotid intima–media thickness measurements. Stroke 28:665–671PubMed
37.
go back to reference Weissberg PL (2000) Coronary disease atherogenesis: current understanding of the causes of atheroma. Heart 83:247–252PubMedCrossRef Weissberg PL (2000) Coronary disease atherogenesis: current understanding of the causes of atheroma. Heart 83:247–252PubMedCrossRef
39.
go back to reference Ames PR, Margarita A, Delgado Alves J, Tommasino C, Iannacone L, Brancaccio V (2002) Anticardiolipin antibody titre and plasma homocysteine level independently predict intima media thickness of carotid arteries in subjects with idiopathic antiphospholipid antibodies. Lupus 11:208–214PubMedCrossRef Ames PR, Margarita A, Delgado Alves J, Tommasino C, Iannacone L, Brancaccio V (2002) Anticardiolipin antibody titre and plasma homocysteine level independently predict intima media thickness of carotid arteries in subjects with idiopathic antiphospholipid antibodies. Lupus 11:208–214PubMedCrossRef
40.
go back to reference Vlachoyiannopoulus PG, Kanellopoulus PG, Ioannidis JP, Tektonidou MG, Mastorakou I, Moutsopoulos HM (2003) Atherosclerosis in premenopausal women with antiphospholipid syndrome and systemic lupus erythematosus: a controlled study. Rheumatology 42:645–651CrossRef Vlachoyiannopoulus PG, Kanellopoulus PG, Ioannidis JP, Tektonidou MG, Mastorakou I, Moutsopoulos HM (2003) Atherosclerosis in premenopausal women with antiphospholipid syndrome and systemic lupus erythematosus: a controlled study. Rheumatology 42:645–651CrossRef
41.
go back to reference del Rincon I, Williams K, Stern MP, Freeman GL, O’Leary DH, Escalante A (2003) Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. Arthritis Rheum 48:1833–1840PubMedCrossRef del Rincon I, Williams K, Stern MP, Freeman GL, O’Leary DH, Escalante A (2003) Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. Arthritis Rheum 48:1833–1840PubMedCrossRef
42.
go back to reference Gerli R, Schillaci G, Giordano A, Bocci EB, Bistoni O, Vaudo G, Marchesi S, Pirro M, Ragni F, Shoenfeld Y, Mannarino E (2004) CD4+CD28− T lymphocytes contribute to early atherosclerotic damage in rheumatoid arthritis patients. Circulation 109:2744–2748PubMedCrossRef Gerli R, Schillaci G, Giordano A, Bocci EB, Bistoni O, Vaudo G, Marchesi S, Pirro M, Ragni F, Shoenfeld Y, Mannarino E (2004) CD4+CD28− T lymphocytes contribute to early atherosclerotic damage in rheumatoid arthritis patients. Circulation 109:2744–2748PubMedCrossRef
43.
go back to reference Soltesz P, Der H, Veres K, Laczik R, Sipka S, Szegedi G, Szodoray P (2008) Immunological features of primary anti-phospholipid syndrome in connection with endothelial dysfunction. Rheumatology (Oxford) 47:1628–1634CrossRef Soltesz P, Der H, Veres K, Laczik R, Sipka S, Szegedi G, Szodoray P (2008) Immunological features of primary anti-phospholipid syndrome in connection with endothelial dysfunction. Rheumatology (Oxford) 47:1628–1634CrossRef
Metadata
Title
A comparative study of arterial stiffness, flow-mediated vasodilation of the brachial artery, and the thickness of the carotid artery intima–media in patients with systemic autoimmune diseases
Authors
Pál Soltész
Henriett Dér
György Kerekes
Péter Szodoray
Gabriella Szücs
Katalin Dankó
Yehuda Shoenfeld
Gyula Szegedi
Zoltán Szekanecz
Publication date
01-06-2009
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 6/2009
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-009-1118-y

Other articles of this Issue 6/2009

Clinical Rheumatology 6/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine